Welcome to Kaiser Permanente Institute for Health Policy Forum: Addressing High Drug Pricing
Since 1999, the Institute for Health Policy’s (IHP) mission has been to shape policy and practice with evidence and experience from the nation’s largest private integrated health care delivery and financing organization through publications, expert roundtables, and conferences.
In support of that mission, IHP presents the Kaiser Permanente Institute for Health Policy Forum: Addressing High Drug Pricing, which will convene on April 6 in Washington, D.C. at Kaiser Permanente’s Center for Total Health.
The Institute for Health Policy Forum brings together organizational leaders, industry experts, policy makers, academics, and more who will engage and inspire attendees.
Amy is the vice president and chief pharmacy officer at Kaiser Permanente (KP), where she provides leadership and direction for KP’s clinical and pharmacy operations. Amy came to KP after a 32-year career with the Los Angeles County Department of Health Services, serving as chief pharmacy officer and the hospital pharmacy director for the Los Angeles County LAC+USC Medical Center. Amy is also the president of the California Board of Pharmacy.
She holds a doctor of pharmacy degree from the University of Southern California.
Tony Barrueta is senior vice president of Government Relations for Kaiser Foundation Health Plan, Inc. He oversees Kaiser Permanente’s public policy development and legislative and regulatory policy efforts, leading a team of legislative advocates and policy professionals in Oakland, Sacramento and Washington, D.C.
A native of Washington D.C., Barrueta received a bachelor’s degree in history from Boston College in 1987 and his law degree from the University of Texas at Austin in 1991. He serves as Board Chair for the Public Health Institute and is a member of the boards of directors of the Alliance of Community Health Plans and California Latino Economic Institute.
David is the founder and president of Patients for Affordable Drugs. David Mitchell has an incurable blood cancer called multiple myeloma. The price of his current drugs is $450,000 per year. Like millions of others, David needs innovation and new drugs for his survival, but he believes drugs don’t work if people can’t afford them. After more than 30 years at a D.C. policy communications firm, he retired in December 2016 to devote his full energy to helping change policy to lower prescription drug prices.
Dora is a senior health policy advisor in Sidley Austin’s Government Strategies practice, providing strategic advice on coverage, health care quality and innovation, and payment policy and reimbursement. Dora counsels clients on policy issues related to regulatory and approval processes for medical products, health information technology and data analytics, and population health.
Dora served as counselor to Secretary Kathleen Sebelius at the U.S. Department of Health and Human Services for nearly four years. Prior to this, she staffed Senator Edward Kennedy as deputy director for the Committee on Health, Education, Labor, & Pensions and former Senator Barack Obama as health policy advisor.
She holds a doctor of medicine degree from Vanderbilt University and an MPH from Harvard University.
Fiona Scott Morton
Fiona is a professor of economics at the Yale University School of Management where she has been on the faculty since 1999. Her area of academic research is empirical industrial organization, with a focus on empirical studies of competition in areas such as pricing, entry, and product differentiation. From 2011-12 Professor Scott Morton served as the deputy assistant attorney general for economics at the Antitrust Division of the U.S. Department of Justice, where she helped enforce the nation’s antitrust laws.
She holds a bachelor of arts degree from Yale and a PhD from MIT.
Jane Horvath is a Senior Policy Fellow at the National Academy for State Health Policy, where she works with the Emerging Issues Team and leads efforts to foster state initiatives on drug prices.
Prior to NASHP, Jane worked as a consultant to life sciences foundations and advocacy organizations and held research positions at Johns Hopkins University and MACPAC. Jane spent ten years at Merck working on coverage and reimbursement policies in federal programs. She has worked for Medicaid Directors, the US Senate Finance Committee, and was the Deputy Assistant Secretary for Legislation (Health) at the US Department of Health and Human Services.
Lauren is a health policy expert at Mehlman Castagnetti Rosen & Thomas and the executive director of the Campaign for Sustainable Drug Pricing, a coalition of leaders promoting bipartisan, market-based solutions to lower drug prices in America. Prior to this, she directed the Office of Legislation at the Centers for Medicare and Medicaid Services and led the agency’s interactions with Capitol Hill. She also served as a professional staff member for the House Ways and Means Committee and served under President Obama as the policy director in the Office of Health Reform.
She holds a bachelor of science degree from George Washington University.
Maisha Draves is the Medical Director for Pharmacy in Northern California for The Permanente Medical Group. In this role, she collaborates with the Chair of the Regional Pharmacy & Therapeutics Committee on formulary and pharmacy policy and with the Drug Information Services group on the strategies related to drug shortages and recalls. She provides oversight for Pharmacy related research and develops strategies/agenda for NCAL drug utilization management efforts. She engages the participation of TPMG clinical and thought leads in efforts around appropriate drug use. In addition, Maisha partners with Chiefs Groups regarding status of DRUG initiatives and is the physician partner for shared leadership between TPMG, Regional Pharmacy and Nursing.
Mark McClellan, MD, PhD, is the Robert J. Margolis Professor of Business, Medicine, and Policy, and Director of the Margolis Center for Health Policy at Duke University. He is a physician-economist who focuses on quality and value in health care including payment reform, real-world evidence and more effective drug and device innovation. He is former administrator of the Centers for Medicare & Medicaid Services and former commissioner of the U.S. Food and Drug Administration, where he developed and implemented major reforms in health policy. He was previously Senior Fellow at the Brookings Institution and a faculty member at Stanford University.
Sameer is an associate executive director for The Permanente Medical Group (TPMG), where he oversees Pharmacy, Adult and Family Medicine, and opioid initiatives, among other operations. In addition to his clinical responsibilities, he is involved in resident teaching and serves as secretary and chair of the Governance Committee of the Mid-Atlantic Permanente Medical Group Board. Previously, he served as chair of the Hospital Ethics Committee, chief of medicine at TPMG’s Campbell medical facilities and held several roles on the TPMG Board of Directors.
Sameer is a board certified in Internal Medicine, holding a doctor of medicine degree from University of California, Irvine.
Rena M. Conti
Rena M. Conti, PhD is an Associate Professor at the University of Chicago, Departments of Pediatrics and Public Health Sciences. Dr. Conti is a health economist. Her research is on the organization, financing and regulation of new medical technology.
Peter B. Bach
Peter B. Bach, MD, MAPP is the director of Memorial Sloan Kettering’s Center for Health Policy and Outcomes. Through the Drug Pricing Lab, he and his team educate policymakers, healthcare professionals, industry officials, and patients on drug development and pricing.
He served as a Senior Advisor to the Administrator of the Centers for Medicare and Medicaid Services (CMS) in 2005 and 2006, and Chair of the CMS Expert Panel that developed quality measures for cancer hospitals. He is currently the Vice Chair of the CMS MEDCAC.
Dr. Bach received an AB from Harvard University, an MD at the University of Minnesota and a MAPP from University of Chicago.
Stephen Parodi, MD serves an associate executive director for The Permanente Medical Group with responsibility for hospital operations, inpatient quality, patient safety, care of complex and special needs populations, skilled nursing facilities, home health, hospice, and external communications. He also executive vice president for The Permanente Federation with duties that include external affairs, government relations, communications, and brand. He also serves as a liaison for Kaiser Permanente’s engagement in local and international healthcare delivery initiatives.
Dr. Parodi received his medical degree from Georgetown University, completed his internal medicine residency at Vanderbilt University Medical Center, and infectious disease fellowship at the UCLA Affiliated Program in Infectious Disease.
Steven D. Pearson, MD, MSc is the Founder and President of the Institute for Clinical and Economic Review (ICER), an independent non-profit organization that evaluates the evidence on the value of medical tests, treatments, and delivery system innovations to encourage collaborative efforts to improve patient care and control costs. Prominent among its evidence reports are ICER reviews of new drugs that include full assessments of clinical and cost-effectiveness along with suggested “value-based price benchmarks” to inform policymakers and guide price and coverage negotiation. Dr. Pearson is a Lecturer in the Department of Population Medicine at Harvard Medical School and also serves as Visiting Scientist in the Department of Bioethics at the National Institutes of Health.
Friday, April 6
9:00 a.m. Breakfast
9:30 a.m. Welcome & Introduction
9:45 a.m. Morning Keynote Address: The Patient Perspective
10:15 a.m. The Physician Perspective
11:00 a.m. Break
11:15 a.m. The Public Perspective
11:30 a.m. Panel: The Nature of the Problem
12:30 p.m. Lunchtime Panel: FDA Commissioners on the Problem
1:30 p.m. A Path to Bipartisanship on Drug Pricing
2:00 p.m. Panel: Solutions
2:55 p.m. Themes Emerging from Today’s Forum
3:00 p.m. Adjourn
How to Register
The Kaiser Permanente Institute for Health Policy Forum: Addressing High Drug Pricing is an invite-only event. To register for the event, hosted at Kaiser Permanente’s Center for Total Health, along with room block information please click the registration button below.
Keep in Touch
Interested in learning more about upcoming Institute for Health Policy events or forums? Fill out our contact form below to receive future communications.